SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

TITAN BIOTECH

BSE: 524717 28 Jun 2025
Commodities
₹ 393
Titan Bio-Tech Ltd. specializes in Specialty Chemicals within the Commodities sector.

TITAN BIOTECH - Share Price & Details

Market Cap
₹332.0
High /Low
1,018 / 374.0
Stock P/E
15.4
Book Value
₹186.0
Dividend Yield
0.5
ROCE
16.9
ROE
₹15.0
Face Value
10.0
PEG Ratio
0.58
EVEBITDA
₹11.2
Debt
2.80
CMP / FCF
31.3
Debt to equity
₹0.02
NP Ann
21.5
High price all time
1,018
Piotroski score
₹5.0
Graham Number
330.0
No. Eq. Shares
0.83
Net CF
₹2.29
Net profit
21.5
Price to book value
2.17
Interest Coverage
₹31.5
Low price all time
8.57
Industry PE
29.9
Reserves
₹145
Free Cash Flow
₹11.6

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Southern Gas Ltd.,NANANANA0.050.03
Indo Gulf Industries Ltd.,NANANANA0
TITAN BIOTECH LTD.NANANANA332.015.4
PODDAR PIGMENTS LTD.885.7751.41871.734.8531513.8
Chembond Material TechnologiesNANANANA31319.2

Peer Comparison Chart


About TITAN BIOTECH

Titan Bio-Tech Ltd., with Security Code 524717, is a leading player in the Specialty Chemicals industry, categorized under the Commodities sector, offering Equity instruments.


Latest News

Taiwan Biotech Startup Raises $20M in Nasdaq IPO to Transform Urinary Disease Treatment Market

(19 Jun 2025)
Plant-derived drug developer Jyong Biotech secures $20M IPO funding, allocating 40% to Phase III trials. See detailed pipeline plans and...
Read more →

MENS - Jyong Biotech Ltd. Latest Stock News & Market Updates

(17 Jun 2025)
Stay updated on Jyong Biotech Ltd. (MENS) with the latest stock news, press releases, earnings reports and financial insights.
Read more →

NT219 Cancer Drug Targets $5B Market: Phase 2 Trial Launches After Promising Early Results

(17 Jun 2025)
Novel dual-pathway targeting drug NT219 advances to Phase 2 after showing partial responses in Phase 1. $5B head and neck cancer market...
Read more →

Taiwan's Jyong Biotech Makes Nasdaq Debut: $20M IPO Targets Breakthrough in Urinary Disease Treatment

(17 Jun 2025)
Taiwan-based biotech firm launches $20M IPO to advance urinary disease drug pipeline. See clinical trial allocations and development roadmap...
Read more →

Collagen Peptide and Gelatin Market is expected to reach USD 9.4

(16 Jun 2025)
Press release - Exactitude Consultancy - Collagen Peptide and Gelatin Market is expected to reach USD 9.4 billion by 2034, driven by rising...
Read more →

How has been the historical performance of the Titan Biotech?

(11 Jun 2025)
Titan Biotech has experienced fluctuating financial performance, with net sales increasing from Rs 64.91 crore in March 2019 to Rs 164.07 crore in March...
Read more →